Literature DB >> 25185554

Misfolding of vWF to pathologically disordered conformations impacts the severity of von Willebrand disease.

Alexander Tischer1, Pranathi Madde1, Laurie Moon-Tasson1, Matthew Auton2.   

Abstract

The primary hemostatic von Willebrand factor (vWF) functions to sequester platelets from rheological blood flow and mediates their adhesion to damaged subendothelium at sites of vascular injury. We have surveyed the effect of 16 disease-causing mutations identified in patients diagnosed with the bleeding diathesis disorder, von Willebrand disease (vWD), on the structure and rheology of vWF A1 domain adhesiveness to the platelet GPIbα receptor. These mutations have a dynamic phenotypical range of bleeding from lack of platelet adhesion to severe thrombocytopenia. Using new rheological tools in combination with classical thermodynamic, biophysical, and spectroscopic metrics, we establish a high propensity of the A1 domain to misfold to pathological molten globule conformations that differentially alter the strength of platelet adhesion under shear flow. Rheodynamic analysis establishes a quantitative rank order between shear-rate-dependent platelet-translocation pause times that linearly correlate with clinically reported measures of patient platelet counts and the severity of thrombocytopenia. These results suggest that specific secondary structure elements remaining in these pathological conformations of the A1 domain regulate GPIbα binding and the strength of vWF-platelet interactions, which affects the vWD functional phenotype and the severity of thrombocytopenia.
Copyright © 2014 Biophysical Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25185554      PMCID: PMC4156683          DOI: 10.1016/j.bpj.2014.07.026

Source DB:  PubMed          Journal:  Biophys J        ISSN: 0006-3495            Impact factor:   4.033


  56 in total

Review 1.  Diagnosis and classification of von Willebrand disease: a review of the differential utility of various functional von Willebrand factor assays.

Authors:  Emmanuel J Favaloro
Journal:  Blood Coagul Fibrinolysis       Date:  2011-10       Impact factor: 1.276

2.  Ristocetin--a new tool in the investigation of platelet aggregation.

Authors:  M A Howard; B G Firkin
Journal:  Thromb Diath Haemorrh       Date:  1971-10-31

3.  Conformational changes in the A1 domain of von Willebrand factor modulating the interaction with platelet glycoprotein Ibalpha.

Authors:  S Miyata; S Goto; A B Federici; J Ware; Z M Ruggeri
Journal:  J Biol Chem       Date:  1996-04-12       Impact factor: 5.157

4.  Defect of heparin binding in plasma and recombinant von Willebrand factor with type 2 von Willebrand disease mutations.

Authors:  G Rastegar-Lari; N Ajzenberg; A S Ribba; V Vereycken-Holler; P Legendre; B Villoutreix; D Meyer; D Baruch
Journal:  Thromb Haemost       Date:  2001-12       Impact factor: 5.249

5.  Laboratory tests for measurement of von Willebrand factor show poor agreement among different centers: results from the United Kingdom National External Quality Assessment Scheme for Blood Coagulation.

Authors:  Steve Kitchen; Ion Jennings; Tim A L Woods; Dianne P Kitchen; Isobel D Walker; Francis E Preston
Journal:  Semin Thromb Hemost       Date:  2006-07       Impact factor: 4.180

6.  Changes in thermodynamic stability of von Willebrand factor differentially affect the force-dependent binding to platelet GPIbalpha.

Authors:  Matthew Auton; Erik Sedlák; Jozef Marek; Tao Wu; Cheng Zhu; Miguel A Cruz
Journal:  Biophys J       Date:  2009-07-22       Impact factor: 4.033

7.  von Willebrand disease type B: a missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib.

Authors:  I Rabinowitz; E A Tuley; D J Mancuso; A M Randi; B G Firkin; M A Howard; J E Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

Review 8.  Genotype/phenotype association in von Willebrand disease: is the glass half full or empty?

Authors:  D Lillicrap
Journal:  J Thromb Haemost       Date:  2009-07       Impact factor: 5.824

9.  A molten globule intermediate of the von Willebrand factor A1 domain firmly tethers platelets under shear flow.

Authors:  Alexander Tischer; Pranathi Madde; Luis M Blancas-Mejia; Matthew Auton
Journal:  Proteins       Date:  2013-11-22

10.  Platelet glycoprotein Ibalpha forms catch bonds with human WT vWF but not with type 2B von Willebrand disease vWF.

Authors:  Tadayuki Yago; Jizhong Lou; Tao Wu; Jun Yang; Jonathan J Miner; Leslie Coburn; José A López; Miguel A Cruz; Jing-Fei Dong; Larry V McIntire; Rodger P McEver; Cheng Zhu
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

View more
  19 in total

1.  The heparin binding domain of von Willebrand factor binds to growth factors and promotes angiogenesis in wound healing.

Authors:  Jun Ishihara; Ako Ishihara; Richard D Starke; Claire R Peghaire; Koval E Smith; Thomas A J McKinnon; Yoji Tabata; Koichi Sasaki; Michael J V White; Kazuto Fukunaga; Mike A Laffan; Matthias P Lutolf; Anna M Randi; Jeffrey A Hubbell
Journal:  Blood       Date:  2019-04-11       Impact factor: 22.113

2.  Glycosylation sterically inhibits platelet adhesion to von Willebrand factor without altering intrinsic conformational dynamics.

Authors:  Alexander Tischer; Venkata R Machha; Laurie Moon-Tasson; Linda M Benson; Matthew Auton
Journal:  J Thromb Haemost       Date:  2019-09-03       Impact factor: 5.824

3.  Enhanced Local Disorder in a Clinically Elusive von Willebrand Factor Provokes High-Affinity Platelet Clumping.

Authors:  Alexander Tischer; Venkata R Machha; Juan P Frontroth; Maria A Brehm; Tobias Obser; Reinhard Schneppenheim; Leland Mayne; S Walter Englander; Matthew Auton
Journal:  J Mol Biol       Date:  2017-05-19       Impact factor: 5.469

4.  A discontinuous autoinhibitory module masks the A1 domain of von Willebrand factor.

Authors:  W Deng; Y Wang; S A Druzak; J F Healey; A K Syed; P Lollar; R Li
Journal:  J Thromb Haemost       Date:  2017-08-09       Impact factor: 5.824

5.  The Von Willebrand Factor A1-Collagen III Interaction Is Independent of Conformation and Type 2 Von Willebrand Disease Phenotype.

Authors:  Venkata R Machha; Alexander Tischer; Laurie Moon-Tasson; Matthew Auton
Journal:  J Mol Biol       Date:  2016-11-24       Impact factor: 5.469

6.  Structural origins of misfolding propensity in the platelet adhesive von Willebrand factor A1 domain.

Authors:  Michael T Zimmermann; Alexander Tischer; Steven T Whitten; Matthew Auton
Journal:  Biophys J       Date:  2015-07-21       Impact factor: 4.033

7.  Chaperonin-Based Biolayer Interferometry To Assess the Kinetic Stability of Metastable, Aggregation-Prone Proteins.

Authors:  Wendy A Lea; Pierce T O'Neil; Alexandra J Machen; Subhashchandra Naik; Tapan Chaudhri; Wesley McGinn-Straub; Alexander Tischer; Matthew T Auton; Joshua R Burns; Michael R Baldwin; Karen R Khar; John Karanicolas; Mark T Fisher
Journal:  Biochemistry       Date:  2016-08-19       Impact factor: 3.162

8.  Mutational Constraints on Local Unfolding Inhibit the Rheological Adaptation of von Willebrand Factor.

Authors:  Alexander Tischer; James C Campbell; Venkata R Machha; Laurie Moon-Tasson; Linda M Benson; Banumathi Sankaran; Choel Kim; Matthew Auton
Journal:  J Biol Chem       Date:  2015-12-16       Impact factor: 5.157

Review 9.  Mechanisms of platelet clearance and translation to improve platelet storage.

Authors:  M Edward Quach; Wenchun Chen; Renhao Li
Journal:  Blood       Date:  2018-02-23       Impact factor: 22.113

10.  Evidence for the Misfolding of the A1 Domain within Multimeric von Willebrand Factor in Type 2 von Willebrand Disease.

Authors:  Alexander Tischer; Maria A Brehm; Venkata R Machha; Laurie Moon-Tasson; Linda M Benson; Katelynn J Nelton; Rachel R Leger; Tobias Obser; Marina Martinez-Vargas; Steven T Whitten; Dong Chen; Rajiv K Pruthi; H Robert Bergen; Miguel A Cruz; Reinhard Schneppenheim; Matthew Auton
Journal:  J Mol Biol       Date:  2019-10-17       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.